Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia

The BCR-ABL kinase inhibitor imatinib has shown significant efficacy in chronic myeloid leukemia (CML) and is the standard front-line therapy for patients in chronic phase. However, a substantial number of patients are either primarily refractory or acquire resistance to imatinib. While a number of...

Descripción completa

Detalles Bibliográficos
Autor principal: Li, Shaoguang
Formato: Texto
Lenguaje:English
Publicado: Informa Healthcare 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430171/
https://www.ncbi.nlm.nih.gov/pubmed/18203007
http://dx.doi.org/10.1080/10428190701713689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430171/
https://www.ncbi.nlm.nih.gov/pubmed/18203007
http://dx.doi.org/10.1080/10428190701713689

Ejemplares similares